AIHTA - Publications - Search - Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) for the treatment of patients with mismatch repair deficient (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer

Wolf, S. (2021): Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) for the treatment of patients with mismatch repair deficient (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer. Oncology Fact Sheet Nr. 51.

[thumbnail of Oncology Fact Sheet Nr.51.pdf]
Preview
PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
114kB

Item Type:Oncology Fact Sheet
Subjects:QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
QZ Pathology > QZ 200-380 Neoplasms.Cysts
WB Practice of medicine > WB 300-962 Therapeutics
WI Digestive system > WI 400-560 Intestines
WI Digestive system > WI 600-650 Anus. Rectum
Language:English
Series Name:Oncology Fact Sheet Nr. 51
Deposited on:28 Jun 2021 13:56
Last Modified:28 Jun 2021 15:28

Repository Staff Only: item control page